In 2024, Regeneron Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Regeneron Pharmaceuticals has also provided a category-level breakdown for 7 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 80,300a | 69,600a | 65,800a | |
Total Scope 2 | ||||
Market-Based | 40,400a | 29,900a | 28,500a | |
Location-Based | 57,000a | 53,100a | 46,400a | |
Total Scope 3 | 1,344,820a | 872,876a | 689,242a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 5.6541a | 5.306a | 5.4054a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals amounted to 137,300 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals increased by 11.9%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Regeneron Pharmaceuticals were 80,300 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Regeneron Pharmaceuticals's Scope 1 emissions have increased by 39.65%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 1 emissions increased by 15.37%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Regeneron Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 40,400 tCO₂e using the market-based method and 57,000 tCO₂e using the location-based method.a
Since 2019, Regeneron Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 56.16%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Regeneron Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Regeneron Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Regeneron Pharmaceuticals reported 1,344,820 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Regeneron Pharmaceuticals includes a breakdown across 7 of the 15 Scope 3 categories defined by the GHG Protocol, up from 6 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2024, Regeneron Pharmaceuticals reported total Scope 3 emissions of 1,344,820 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Regeneron Pharmaceuticals's Scope 3 emissions have increased by 140.21%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 3 emissions increased by 54.07%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2024, Regeneron Pharmaceuticals reported emissions for 7 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2024, the largest contributors to Regeneron Pharmaceuticals's Scope 3 emissions were:a
In 2024, Regeneron Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 80,300 tCO₂e and total revenues of USD 14,202 millions. This translates into an emissions intensity of 5.65 tCO₂e per millions USD.a
In 2024, Regeneron Pharmaceuticals reported a Scope 1 emissions intensity of 5.65 tCO₂e per millions USD. Compared to the peer group median of 2.64, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Regeneron Pharmaceuticals ranked 16 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Regeneron Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Regeneron Pharmaceuticals reported a total carbon footprint of 1,482,120 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 48.87% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Regeneron Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 90.74% of the company's total carbon footprint, followed by Scope 1 emissions at 5.42%.a